To evaluate the sensitivity of lung cancer cells to pharmacological inhibition of JAK2, we analyzed the GDSC dataset including exome sequencing data, gene expression profiling data, and screening results of 265 cancer drugs in more than 900 cancer cell lines [32, 33], among them 103 are NSCLC cell lines. This evidence concerns the gene JAK2 and non-small cell lung carcinoma.